Monograph Details
|
|
Respiratory Tract
> Asthma/COPD
|
|
XOLAIR |
| Manufacturer |
|
Genentech and Novartis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antiasthmatic (IgE blocker). |
| Generic Name |
|
Omalizumab 150mg/vial; pwd for SC inj after reconstitution; preservative-free. |
| Indications |
|
Moderate to severe persistent asthma in patients with a (+) skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled by inhaled corticosteroids. |
| Children |
|
Not recommended. |
| Adults |
|
Base dose and frequency on baseline serum total IgE level and body weight; see literature. Give by SC inj over 5–10 seconds; max 150mg per inj site. 150–375mg every 2 or 4 weeks. Reevaluate periodically. |
| Precautions |
|
Not for treating acute attacks. Have medications for treating anaphylaxis available, monitor for at least 2 hours after inj; may have delayed reaction. Elevated serum IgE levels may persist for up to 1 year after stopping therapy. Patients at risk of malignancy. Pregnancy (Cat.B). Nursing mothers. |
| Adverse Reactions |
|
Inj site reactions, viral infections, upper respiratory tract infections (eg, sinusitis, pharyngitis), headache; hypersensitivity reactions (discontinue if severe), anaphylaxis (may be fatal), antibody formation, malignancies. |
| How Supplied |
|
Single-use vial—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
